Local modulated electro-hyperthermia in combination with traditional Chinese medicine vs. intraperitoneal chemoinfusion for the treatment of peritoneal carcinomatosis with malignant ascites: A phase II randomized trial

Pang,Clifford  L.K.; Zhang,Xinting; Wang,Zhen; Ou,Junwen; Lu,Yimin; Chen,Pengfei; Zhao,Changlin; Wang,Xiaopu; Zhang,Hongyu; Roussakow,Sergey  V.

doi:10.3892/mco.2017.1221

Local modulated electro-hyperthermia in combination with traditional Chinese medicine vs. intraperitoneal chemoinfusion for the treatment of peritoneal carcinomatosis with malignant ascites: A phase II randomized trial

Authors:
- Clifford L.K. Pang
- Xinting Zhang
- Zhen Wang
- Junwen Ou
- Yimin Lu
- Pengfei Chen
- Changlin Zhao
- Xiaopu Wang
- Hongyu Zhang
- Sergey V. Roussakow
View Affiliations

Affiliations: International Natural Medicine Center, Clifford Hospital, Guangzhou, Guangdong 511495, P.R. China, Scientific Research Center, Clifford Hospital, Guangzhou, Guangdong 511495, P.R. China, Nutrition and Preventive Medicine Center, Clifford Hospital, Guangzhou, Guangdong 511495, P.R. China, Hyperthermia Center, Clifford Hospital, Guangzhou, Guangdong 511495, P.R. China, Nontoxic Integrative Cancer Treatment Center, Clifford Hospital, Guangzhou, Guangdong 511495, P.R. China, Galenic Research Institute for Non‑Specific Pathology, 127051 Moscow, Russia
Published online on: April 10, 2017 https://doi.org/10.3892/mco.2017.1221
Pages: 723-732

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of this study was to develop a safe and non-toxic alternative to the conventional conservative treatment of peritoneal carcinomatosis with malignant ascites (PCMA) by investigating the efficacy and safety of local modulated electro-hyperthermia (mEHT) combined with the traditional Chinese medicine (TCM) ‘Shi Pi’ herbal decoction, compared with standard intraperitoneal chemoinfusion (IPCI). A randomized, controlled, single‑center, open‑label clinical trial (phase II) with two parallel groups (allocation ratio, 1:1) was conducted to investigate the efficacy and safety of mEHT+TCM (study group, SG) vs. standard IPCI (control group, CG) in patients with PCMA by intention‑to‑treat analysis. A total of 260 patients with PCMA were randomly allocated into the two groups (130/130); mEHT was applied for 60 min per session every second day for 4 weeks, for a total of 14 sessions. The TCM decoction was administered orally, at 400 ml daily. In CG, occlusive IPCI with cisplatin (30‑60 mg) and fluorouracil (500‑600 mg/m2) was applied twice, biweekly. The objective response rate (ORR), quality of life (QoL) and adverse event rate (AER) in the two groups were evaluated 1 month after treatment, analyzed and compared. The present study is registered on ClinicalTrials.gov (NCT02638051). No case was lost or excluded (0/260). The ORR in SG was 77.69% (101/130) vs. 63.85% (73/130) in CG (P<0.05). The QoL in SG was 49.23% vs. 32.3% in CG (P<0.05). The AER in SG was 2.3% (3/130) vs. 12.3% (16/130) in CG (P<0.05). All the adverse events were grade I. In conclusion, the combination of mEHT with TCM achieves better control of PCMA compared with standard IPCI, with less toxicity. Both components of the combination are non‑toxic treatments easily tolerated by patients. Thus, this combined treatment may be preferred due to the better benefit-harm balance.

View Figures

View References

1	Ayantunde AA and Parsons SL: Pattern and prognostic factors in patients with malignant ascites: A retrospective study. Ann Oncol. 18:945–949. 2007. View Article : Google Scholar : PubMed/NCBI
2	Sangisetty SL and Miner TJ: Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 4:87–95. 2012. View Article : Google Scholar : PubMed/NCBI
3	Roussakow S: Critical analysis of electromagnetic hyperthermia randomized trials: Dubious effect and multiple biases. Conference Papers in Medicine 2013. 2013. View Article : Google Scholar
4	Roussakow S: The history of hyperthermia rise and decline. Conference Papers in Medicine 2013. 2013. View Article : Google Scholar
5	The American Cancer Society: Hyperthermia to Treat Cancer. http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/hyperthermiaAccessed. February 16–2017.
6	Ma Shenglin: Research progress of thermo-chemo-therapy. Mod Pract Med. 16:256–258. 2004.
7	Szasz A, Szasz N and Szasz O: Oncothermia: Principles and Practices. New York: Springer, NY; pp. 5652011
8	Andocs G, Renner H, Balogh L, Fonyad L, Jakab C and Szasz A: Strong synergy of heat and modulated electromagnetic field in tumor cell killing. Strahlenther Onkol. 185:120–126. 2009. View Article : Google Scholar : PubMed/NCBI
9	Pang CLK: Clinical research on integrative treatment of colon carcinoma with oncothermia and clifford TCM immune Booster. Oncothermia J. 5:24–41. 2012.
10	Ling Y: Traditional Chinese medicine in the treatment of symptoms in patients with advanced cancer. Ann Palliat Med. 2:141–152. 2013.PubMed/NCBI
11	Veith I (translator): The Yellow Emperor's Classic of Internal Medicine. (1972)Revised paperback edition. University of California Press; Berkeley, LA: pp. 912002
12	Zheng Y and Gao F: The recognition of TCM on seroperitoneum of hepatic cirrhosis. J Trad Chinese Med. 5:832008.
13	Zhou D: Oncology of TCM. Guangzhou: Guangdong High Education Publishing House; pp. 902007
14	Chen F: Clinical research of out-of-body high frequency hyperthermia in combination with TCM treating malignant pleural fluid and ascites. J Practical Traditional Chinese Med. 27:686–687. 2011.
15	Zhou L and Zhang S: Clinical observation of adjusted Wu Ling Decoction treating 70 patients with malignant ascites. J Practical Chinese Intern Med. 24:7–711. 2010.
16	Huang X: Observation of Shen Zhu Decoction in combination with endogeny hyperthermia treating 69 patients with malignant ascites. J Practical Chinese Intern Med. 20:3882006.
17	Gong S: Observation of the therapeutic effect of microwave hyperthermia in combination with No2.3 Readjusted Decoction treating malignant pleural fluid and ascites. J Changchun University of Traditional Chinese Med. 27:643–644. 2011.
18	Ji Sheng Fang: (8 juan/(Song) Yan Yonghe zhuan). (In Chinese). Taibei: Taiwan shang wu yin shu guan; pp. 1491975
19	Becker G, Galandi D and Blum HE: Malignant ascites: Systematic review and guideline for treatment. Europ J Cancer. 42:589–597. 2006. View Article : Google Scholar
20	Matharu G, Tucker O and Alderson D: Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg. 98:1225–1235. 2011. View Article : Google Scholar : PubMed/NCBI
21	McRee AJ and O'Neil BH: The role of HIPEC in gastrointestinal malignancies: Controversies and conclusions. Oncology (Williston Park). 29:523–524, C3. 2015.PubMed/NCBI
22	Verhulst J: Effects of bevacizumab and hyperthermia in a rodent model of hyperthermic intraperitoneal chemotherapy (HIPEC). Int J Hyperthermia. 29:62–70. 2013. View Article : Google Scholar : PubMed/NCBI
23	Zeamari S, Floot B, van der Vange N and Stewart FA: Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). Anticancer Res. 23:1643–1648. 2003.PubMed/NCBI
24	Sørensen O, Andersen AM, Kristian A, Giercksky KE and Flatmark K: Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis. J Surg Oncol. 109:521–526. 2014. View Article : Google Scholar : PubMed/NCBI
25	Kroon HM and Thompson JF: Isolated limb infusion: A review. J Surg Oncol. 100:169–177. 2009. View Article : Google Scholar : PubMed/NCBI
26	Di Miceli D, Alfieri S, Caprino P, Menghi R, Quero G, Cina C, Pericoli Ridolfini M and Doglietto GB: Complications related to hyperthermia during hypertermic intraoperative intraperitoneal chemiotherapy (HIPEC) treatment. Do they exist? Eur Rev Med Pharmacol Sci. 16:737–142. 2012.PubMed/NCBI
27	Jafari MD, Halabi WJ, Stamos MJ, Nguyen VQ, Carmichael JC, Mills SD and Pigazzi A: Surgical outcomes of hyperthermic intraperitoneal chemotherapy: Analysis of the american college of surgeons national surgical quality improvement program. JAMA Surg. 149:170–175. 2014. View Article : Google Scholar : PubMed/NCBI
28	Zhenxia Z, Ziwei L and Ran J: Abdominal indwelling catheter drainage combined with intracavitary perfusion chemotherapy for patients with malignant seroperitoneum. J Huaihai Med. 26:306–528. 2008.
29	Chongqi W, Chiping W and Yuying S: The clinical value of 5-FU combined with cisplatin for hyperthermic intraperitoneal chemoinfusion in treating cancerous ascites. Chin J Med Drug Appl. 2:9–10. 2008.
30	de Kock I, Mirhosseini M, Lau F, Thai V, Downing M, Quan H, Lesperance M and Yang J: Conversion of karnofsky performance status (KPS) and Eastern cooperative oncology group performance status (ECOG) to palliative performance scale (PPS), and the interchangeability of PPS and KPS in prognostic tool. J Palliat Care. 29:163–169. 2013.PubMed/NCBI
31	Ovarian cancer including fallopian tube cancer and primary peritoneal carcinoma. NCCN Clinical Practice Guidelines in Oncology. Ver. 3.2014. https://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed. February 16–2017.
32	Zhou Daihan: TCM Oncology. Guangdong High Education Press; 1. 2007, View Article : Google Scholar
33	Sun Yan: Medical Oncology. Beijing: People's Medical Publishing House; pp. 648–649. 2001
34	Hawker GA, Mian S, Kendzerska T and French M: Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 63:(Suppl 11). S240–S252. 2011. View Article : Google Scholar : PubMed/NCBI
35	Common Terminology Criteria for Adverse Events (CTCAE) (v4.03: June 14, 2010) U.S. Department of Health and Human ServicesNational Institutes of Health. National Cancer Institute;
36	Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M and Altman DG: CONSORT: CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. Int J Surg. 10:28–55. 2012. View Article : Google Scholar : PubMed/NCBI
37	Li Z, Zhang L and Li L: Treatment of malignant ascites with hyperthermic perfusion chemotherapy and high-frequency hyperthermia. Med J West China. 22:517–521. 2010.
38	Yu X, Li X, Zhou J, et al: The clinical study of intraperitoneal chemotherapy combined with whole body hyperthermia by using microwave on abdomen for treating malignant peritoneal effusion. J Clin Intern Med. 24:253–255. 2007.
39	Yin J, Dai P and Xie Z: Clinical study of chemotherapeutic hyperthermia intraperitoneal perfusion combined with high frequency hyperthermia for the treatment of malignant ascites. Med J Wuhan University. 28:248–250. 2007.
40	Wang H, Liu P, Wang Y, et al: Effects observation of treating malignant ascites with in vitro radiofrequency thermotherapy combined intraperitoneal perfusion chemotherapy. China Clinicians. 43:31–32. 2015.
41	Meggyeshazi N, Andocs G, Balogh L, Balla P, Kiszner G, Teleki I, Jeney A and Krenacs T: DNA fragmentation and caspase-independent programmed cell death by modulated electrohyperthermia. Strahlenther Onkol. 190:815–822. 2014. View Article : Google Scholar : PubMed/NCBI
42	Andocs G, Meggyeshazi N, Balogh L, Spisak S, Maros ME, Balla P, Kiszner G, Teleki I, Kovago C and Krenacs T: Upregulation of heat shock proteins and the promotion of damage-associated molecular pattern signals in a colorectal cancer model by modulated electrohyperthermia. Cell Stress Chaperones. 20:37–46. 2015. View Article : Google Scholar : PubMed/NCBI
43	Tsang YW, Huang CC, Yang KL, Chi MS, Chiang HC, Wang YS, Andocs G, Szasz A, Li WT and Chi KH: Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy. BMC Cancer. 15:7082015. View Article : Google Scholar : PubMed/NCBI
44	Akutsu Y, Tamura Y, Murakami K, et al: Can modulated electro-hyperthermia (mEHT) elicit immune reaction? -From basic and clinical research. Therm Med. 30:62(WS1WS1-3). 2014.
45	Sugarbaker H: Technical Handbook for the Integration of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy into the Surgical Management of Gastrointestinal and Gynecologic Malignancy. 4th. Ludann Company; Grand Rapids, MI: pp. 672005